• 产品描述： TBK1/IKKε-IN-5 (compound 1) 是一种 TANK-binding kinase 1 (TBK1) 和 IκB kinase-ε (IKKε/IKK-i) 的双重抑制剂，对于TBK1和IKKε的IC50值分别为1.0 nM和5.6 nM。TBK1 /IKKε被抑制可增强对PD-1阻断的反应，从而有效地预测了体内的肿瘤反应

• 靶点： TBK1(Cell-free assay):1.0 nM; IKKε(Cell-free assay):5.6 nM;IκB/IKK

• 体外研究：
  TBK1/IKKε-IN-5(compound 1) effectively blocks immune suppressive cytokine elaboration by CT26 cell line spheroids, without cytotoxic effects, and enhances secretion of IL-2 and IFN-γ from purified CD4+ and CD8+ T cells from healthy human donors and IL-2 from Jurkat human T-cell leukemia cells. Ex vivo addition of TBK1/IKKε-IN-1(compound 1) to PD-1 blockade enhances killing of CT26 MDOTS, associated with decreased levels of CCL4, CCL3, and IL-1β and induction of cytokines involved in activated innate immune responses

• 体内研究：
  Balb/c mice bearing CT26 tumors are treated with TBK1/IKKε-IN-1(compound 1) ± anti-PD-L1. Consistent with MDOTS profiling data, greater tumor control and longer survival is evident with TBK1/IKKε-IN-1(compound 1) + anti-PD-L1 than with either TBK1/IKKε-IN-1(compound 1) or anti-PD-L1 alone. Reimplantation of CT26 into mice with exceptional responses to combination therapy shows no growth, whereas EMT-6 implanted tumors grow normally, suggesting induction of immunologic memory of CT26 cells in mice treated with TBK1/IKKε-IN-1(compound 1) + anti-PD-L1. Therefore, MDOTS profiling effectively recapitulates the in vivo response to PD-1 blockade +/− TBK1/IKKε inhibition, highlighting the potential of ex vivo screening in MDOTS to develop combination immunotherapies.

• 细胞实验： Cell lines: HCT116 cells, human CD4+ T cells, human CD8+ T cells Concentrations: 1 μM Incubation Time: 1 h, 24 h, 96 h Method: Interleukin-2 and interferon gamma analysis—Freshly isolated human CD4+ and CD8+ T cells are spun down and resuspended in serum free X-vivo15 media supplemented with 5 ng/mL IL-17 and incubated overnight at 37°C. Cells are plated on anti-CD3 coated plates with 2 μg/mL anti-CD28. Cells are treated in replicate plates with a dose-titration of TBK1/IKKε-IN-1(compound 1) for 24 hours for IL-2 and 96 hours for IFNγ. IL-2 and IFNγ in the supernatant are measured using single-or multi-plex immunoassay. Jurkat T cell leukemia cells plated on anti-CD3 coated plates are treated with a dose titration of TBK1/IKKε-IN-1(compound 1) for 24 hours.

• 动物实验： Animal Models: 11-12 week old female Balb/c mice implanted with 1×106 CT26 colon carcinoma cells. Dosages: 40 mg/kg Administration: Oral gavage

• 参考文献：
  1. Russell WJ, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 Feb;8(2):196-215.

• 溶解性： Soluble  in  DMSO

• 保存条件： -20°C

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	1.947 ml	9.735 ml	19.471 ml
  5 mM	0.389 ml	1.947 ml	3.894 ml
  10 mM	0.195 ml	0.974 ml	1.947 ml
  50 mM	0.039 ml	0.195 ml	0.389 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *